Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 10;7(1):361.
doi: 10.1038/s41392-022-01216-3.

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair-deficient, locally advanced rectal cancer

Mi Mi  1   2 , Chenyang Ye  3   4 , Ying Yuan  5   6
Affiliations
Comment

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair-deficient, locally advanced rectal cancer

Mi Mi et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PD-1 blockade as neoadjuvant therapy in DNA dismatch repair–deficient colorectal cancers. a Summary of published clinical trials of neoadjuvant immunotherapy in dMMR, locally advanced CRCs. b The administration of anti-PD-1 antibody dostarlimab achieved clinical complete remission in the patients with dMMR, locally advanced rectal cancer. dMMR mismatch repair-deficiency, CRC colorectal cancer, pCR pathological complete response, cCR clinical complete response, PD-1 programmed death protein 1, PD-L1 programmed death ligand-1. Panel b was generated on Biorender.com
See this image and copyright information in PMC

Comment on

  • PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. Cercek A, et al. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660797 Free PMC article. Clinical Trial.

References

    1. Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 2022;386:2363–2376. doi: 10.1056/NEJMoa2201445. - DOI - PMC - PubMed
    1. Verschoor YL, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. J. Clin. Oncol. 2022;40:3511–3511. doi: 10.1200/JCO.2022.40.16_suppl.3511. - DOI
    1. Sinicrope FA. Lynch syndrome-associated colorectal cancer. N. Engl. J. Med. 2018;379:764–773. doi: 10.1056/NEJMcp1714533. - DOI - PubMed
    1. Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 2018;36:773–779. doi: 10.1200/JCO.2017.76.9901. - DOI - PubMed
    1. Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances